Tag: file

Not for dissemination in the United States of America

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Rising search trends for “fireproof document safe,” “estate planning organizer,” and “emergency binder kit” spotlight ICE Box System as a non-digital solution for families protecting vital records and valuables at home.

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together with the Series A-2 Warrants, the “Existing Warrants”) at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

BOCA RATON, FL, July 08, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 47,272 Solana (“SOL”) at an average purchase price of $149.09 and valued at approximately $7.03 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 690,420 SOL and SOL equivalents, valued at approximately $102.7 million, inclusive of staking rewards. The latest purchase marks a +64.1% increase in the Company’s SOL and SOL equivalent holdings compared to 420,690 SOL held 60 days prior.

Materials testing enables selection of graphite grade and licensing for its Generation IV Integral Molten Salt Reactor (IMSR) nuclear technology, designed to supply high- temperature, clean, firm and flexible thermal and electric energy, with sector-competitive economics and leading time-to-market at fleet scale

Basel, July 8, 2025 – Novartis today announced Coartem^® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet^® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

Investors can contact the law firm at no cost to learn more about recovering their losses